Jean Luc Plantier

Title: The Innovations of Jean Luc Plantier

Introduction

Jean Luc Plantier is a notable inventor based in Grigny, France. He has made significant contributions to the field of biotechnology, particularly in the development of gene therapy techniques. With a total of 3 patents to his name, Plantier's work focuses on enhancing blood coagulation factors, which are crucial for treating various medical conditions.

Latest Patents

One of Plantier's latest patents is the "Modified factor VIII cDNA." This invention describes a modified Factor VIII cDNA in which the B-domain of the wild-type Factor VIII cDNA has been deleted. A truncated Factor IX intron 1 has been inserted in one or more locations of the Factor VIII cDNA. This modified Factor VIII cDNA may be utilized for higher yield production of Factor VIII in vitro, as well as in a transfer vector for gene therapy. Another significant patent is the "DNA-constructs of blood clotting factors and P-Selectin." This DNA construct encodes a fusion protein comprising an amino acid sequence of a blood clotting factor like Factor IX and an amino acid sequence of the cytoplasmic domain of P-Selectin. Such a construct may be used for the somatic gene therapy of patients suffering from a deficiency of a blood coagulation factor.

Career Highlights

Jean Luc Plantier is currently associated with Aventis Behring GmbH, a company known for its advancements in biopharmaceuticals. His work at the company has allowed him to focus on innovative solutions for blood-related disorders.

Collaborations

Plantier collaborates with various professionals in his field, including Claude Négrier, who is also involved in research related to blood coagulation factors. Their combined expertise contributes to the advancement of gene therapy techniques.

Conclusion

Jean Luc Plantier's contributions to biotechnology and gene therapy are noteworthy. His innovative patents and collaborations reflect his commitment to improving medical treatments for blood coagulation disorders.